Publications by authors named "G Bagetta"

Background: According to scientific literature, some 99% of patients affected by Alzheimer's disease (AD) suffer from behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPSs). In particular, agitation is one of the most difficult disorders to treat. States of agitation represent a very serious problem as they make these subjects dangerous for themselves and others and worsen as the disease advances.

View Article and Find Full Text PDF

Amitriptyline is a tricyclic antidepressant commonly used for depressive disorders and is prescribed off-label for several neurological conditions like neuropathic pain, migraines and anxiety. Besides their action on the reuptake of monoaminergic neurotransmitters, tricyclic antidepressants interact with several additional targets that may contribute to either therapeutic or adverse effects. Here, we investigated the effects of amitriptyline on proliferation and autophagy (i.

View Article and Find Full Text PDF

Ischemic preconditioning (PC) induced by a sub-lethal cerebral insult triggers brain tolerance against a subsequent severe injury through diverse mechanisms, including the modulation of the immune system. Tumor necrosis factor (TNF)-α-stimulated gene 6 (TSG-6), a hyaluronate (HA)-binding protein, has recently been involved in the regulation of the neuroimmune response following ischemic stroke. Thus, we aimed at assessing whether the neuroprotective effects of ischemic PC involve the modulation of TSG-6 in a murine model of transient middle cerebral artery occlusion (MCAo).

View Article and Find Full Text PDF
Article Synopsis
  • Approximately 57.4 million people worldwide are affected by dementia, with behavioral and psychological symptoms (BPSD), particularly agitation, being prevalent and often challenging to manage.
  • The BRAINAID trial tested a nanotechnology device, NanoBEO, on 29 elderly patients (65+) with severe dementia to evaluate its effectiveness in reducing agitation and pain, utilizing a randomized and placebo-controlled design.
  • Results indicated that NanoBEO significantly reduced agitation levels and frequency by 28% after 4 weeks, and showed notable pain relief (45.46% improvement) after just 1 week, without requiring additional medications.
View Article and Find Full Text PDF

The global impact of dementia is an increasing area of concern and, according to the Alzheimer's Disease International (ADI) World Alzheimer Report 2021, up to 90% of dementia patients in low- and middle-income countries are not diagnosed [...

View Article and Find Full Text PDF